This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

AssureRx Health Expands Management Team To Support Increasing Business Growth





MASON, Ohio, Dec. 11, 2012 /PRNewswire/ -- AssureRx Health, Inc. today announced four key additions to its leadership team. The management appointments coincide with the need to support increasing GeneSightRx pharmacogenomic testing services, which support healthcare providers in medication selection and the managing of side effects for patients with neuropsychiatric and other disorders.

"We continue to experience rapid adoption of our pharmacogenomic treatment support products that assist clinicians in selecting medications for patients with neuropsychiatric disorders. The additional management appointments enhance our capabilities in pharmacogenomic clinical trial development, new product development, pharmaceutical industry services, high throughput laboratory test operations, market development, and clinician education," said James S. Burns, president and CEO of AssureRx Health. "Our goal is to build the leading personalized medicine company offering pharmacogenomic treatment decision support solutions for neuropsychiatric, pain, ADHD, and other disorders."

Bryan M. Dechairo, PhD, Senior Vice President, Medical Affairs & Strategic Alliances, is responsible for clinical development of current and future products, as well as alliances with academic, pharmaceutical, and genomic partnerships. Bryan was previously head of Extramural Research and Development at Medco Research Institute, responsible for translating pharmacogenomics into medical and pharmacy practice innovations to improve Medco member health outcomes, as well as business development and strategic alliances impacting Medco's research through to commercial products. Prior to joining Medco, Bryan led a multi-disciplinary team of scientists and clinicians to deliver novel biomarkers for drug development as Neuroscience Lead and Director of Molecular Medicine at Pfizer Global Research and Development. He also held drug target discovery or diagnostic development positions at Oxagen, Sequana Therapeutics, and Roche Molecular Systems. Bryan received a PhD in complex human genetics from the Institute of Childs Health at the University College of London.

Stephen E. King, Vice President, Marketing, is responsible for overall AssureRx Health marketing efforts to increase awareness and adoption of the GeneSightRx product line, as well as corporate communications and advocacy relations. Stephen brings more than 20 years of pharmaceutical/biotech commercial expertise to AssureRx Health, with the vast majority dedicated to the CNS/neuroscience therapeutic area. Most recently, he served as Vice President of Commercial Operations at Alkermes, where he led all marketing and sales activities for the portfolio of products. His prior experience has also included the launch of several blockbuster pharmaceutical brands including Paxil and Effexor XR during his tenure with SmithKline Beecham Pharmaceuticals and Wyeth, respectively. Stephen has directed multiple new product launches in both domestic and international markets, and brings to AssureRx Health broad therapeutic area expertise including experience in CNS/neurosciences, pain, addiction, women's health, and endocrinology.

Rao V. Mulpuri, PhD, MBA, Vice President, Laboratory Operations, is responsible for all AssureRx Health multi-site commercial laboratory testing. Rao previously served as Director, Scientific Operations at the Catholic Health Initiatives Center for Translational Research (CHIC), responsible for establishing operational, informatics, IT, quality and regulatory strategies, development and implementation of molecular diagnostic tests (LDTs), and IT systems for electronic health records and genomic data. At Beckman Coulter Genomics, Rao was responsible for managing a CLIA-certified, cGMP/GLP compliant molecular genomics, biobanking and biologics testing facility. His experience also includes operating management positions at Cogenics/Clinical Data, Icoria/Cogenics, and Paradigm Genetics/Icoria. Rao received a PhD in physiology and biochemistry from Vikram University and an MBA from the University of North Carolina.

Scott M. Roth, Vice President, Product Development, has been promoted to lead the AssureRx Health Product Development team in building and supporting AssureRx Health treatment decision product offerings and the AssureRx Health LIMS system. Scott has been responsible for leading development of both AssureRx Health platform software architecture and commercial product software. Scott has extensive prior experience in software product development covering military defense, airline ticketing, credit card, and other applications. Previously, Scott served as Software Development Manager at Domin-8 Enterprise Solutions, managing and leading a team of software developers building property management Microsoft Windows and web based applications. At Spotlight Solutions, Scott was responsible for design and development of the corporate portal and software products.  At Attachmate Corporation, Scott was involved in developing some of the first commercially available e-commerce and e-banking web applications, and custom software applications for the United States Air Force and United Airlines. 

About AssureRx Health

AssureRx Health, Inc. is a personalized medicine company that specializes in pharmacogenomics dedicated to helping physicians determine the right drug for individual patients suffering from neuropsychiatric and other disorders. The company was founded to commercialize industry-leading personalized medicine technology for neuropsychiatric disorders. Cincinnati Children's Hospital Medical Center and Mayo Clinic are equity holders and technology collaborators.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs